These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
72603-0118 Market Analysis and Financial Projection
The drug associated with NDC 72603-0118 is Memantine Hydrochloride, an NMDA receptor antagonist used to treat moderate-to-severe Alzheimer’s dementia. Below is an analysis of its market and price projections based on available data:
Market Analysis
Current Market Landscape:
Memantine’s global market is valued at $1.16 billion as of 2024 and is projected to grow at a 5.9% CAGR through 2033 [11][17].
Growth drivers include:
Rising Alzheimer’s prevalence (over 6 million U.S. cases in 2025) [12][15].
Expansion of generic versions post-patent expiry (e.g., Lupin’s 2018 U.S. launch) [14].
Ongoing clinical trials for new indications (e.g., Suven Life Sciences’ Phase II trials for combination therapies) [17].
Regional Dynamics:
North America dominates (>40% market share) due to high generic adoption and aging populations [14].
Asia-Pacific is the fastest-growing region, driven by cost-effective generic manufacturing (e.g., Dr. Reddy’s 2018 launch in India) [14].
Competitive Landscape:
Key players: Merz Pharmaceuticals, Lupin, Allergan, and Sun Pharma [17].
Price competition intensifies as generics account for >70% of prescriptions [9][12].
Price Projections
Current Pricing:
Average Wholesale Price (AWP) for Memantine Hydrochloride tablets (NDC 72603-0118-01) was $0.38 per unit as of January 2023 [4].
Future Trends:
Short-term (2025–2027): Prices may rise modestly (2–4% annually) due to inflation and production costs but remain constrained by generic competition [6][11].
Long-term (2030+): Prices could stabilize or decline as more generics enter emerging markets [14].
Influencing Factors:
Regulatory policies: FDA approvals for new formulations (e.g., extended-release capsules) may temporarily boost branded prices [15].
Supply chain: Raw material costs for NMDA blockers could impact margins [17].
Risks and Opportunities
Factor
Impact
Rising Alzheimer’s cases
Increases demand but pressures healthcare budgets [11][15].
Patent expirations
Accelerates generic adoption, reducing margins for originators [14][17].
Emerging markets
High growth potential in Asia and Latin America with untapped demand [14].
"The Alzheimer’s drug market will grow steadily, but price ceilings for generics will limit revenue potential unless novel formulations emerge." – Industry Analyst [11].
Key stakeholders should focus on differentiating through combination therapies or targeted delivery systems to mitigate price erosion.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
